てんかん(癲癇)の疫学予測

DelveInsightが発行した調査報告書(DELV803008)
◆英語タイトル:Epilepsy -Epidemiology Forecast
◆商品コード:DELV803008
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥367,250見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD6,500 ⇒換算¥734,500見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD9,750 ⇒換算¥1,101,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Epilepsy – Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Epilepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Epilepsy Epidemiology
The Epilepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Epilepsy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
According to DelveInsight, the prevalent cases of Epilepsy was 7,649,695 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Epilepsy with 4,007,026 prevalent cases in 2016 followed by Germany.

Epilepsy Epidemiology Segmentation
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The disease epidemiology covered in the report is segmented by sex-specific [Male and Female] and sub-type [Focal/ Partial, Generalized, Unclassified]. The report further covers prevalence of Tuberous Sclerosis Complex (TSC) associated Epilepsy.

Report Scope
• The report covers detailed overview of Epilepsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Epilepsy
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM

Key strengths
• 10 Year Forecast of Epilepsy epidemiology
• 7MM Coverage
• Total Prevalent Cases of Epilepsy
• Prevalent Cases according to segmentation: Gender-specific prevalence, sub-type specific prevalence and prevalence of Tuberous Sclerosis Complex (TSC) associated Epilepsy
Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

【レポートの目次】

1. Report Summary 1
2. Epilepsy Disease Background 10
2.1. Introduction 10
2.2. Causes 11
2.3. Symptoms 11
2.4. Classification 12
2.5. Risk factors 16
2.6. Diagnosis 16
2.7. TSC Mutations in Epilepsy 18
2.8. Current Treatment & Medical Practices 19
3. Epidemiology and Patient Population 20
3.1. Key Points 20
3.2. United States 21
3.2.1. Prevalence of Epilepsy in United States 21
3.2.2. Gender specific prevalence in United States 23
3.2.3. Sub-type specific prevalence in United States 24
3.2.4. Prevalence of TSC associated Epilepsy in the United States 25
3.3. Germany 26
3.3.1. Prevalence of Epilepsy in Germany 26
3.3.2. Gender specific prevalence in Germany 28
3.3.3. Sub-type specific prevalence in Germany 29
3.3.4. Prevalence of TSC associated Epilepsy in the Germany 30
3.4. France 31
3.4.1. Prevalence of Epilepsy in France 31
3.4.2. Gender specific prevalence in France 33
3.4.3. Sub-type specific prevalence in France 34
3.4.4. Prevalence of TSC associated Epilepsy in the France 35
3.5. Italy 36
3.5.1. Prevalence of Epilepsy in Italy 36
3.5.2. Gender specific prevalence in Italy 38
3.5.3. Sub-type specific prevalence in Italy 39
3.5.4. Prevalence of TSC associated Epilepsy in the Italy 40
3.6. Spain 41
3.6.1. Prevalence of Epilepsy in Spain 41
3.6.2. Gender specific prevalence in Spain 43
3.6.3. Sub-type specific prevalence in Spain 44
3.6.4. Prevalence of TSC associated Epilepsy in the Spain 45
3.7. United Kingdom 46
3.7.1. Prevalence of Epilepsy in United Kingdom 46
3.7.2. Gender specific prevalence in United Kingdom 48
3.7.3. Sub-type specific prevalence in United Kingdom 49
3.7.4. Prevalence of TSC associated Epilepsy in the UK 50
3.8. Japan 51
3.8.1. Prevalence of Epilepsy in Japan 51
3.8.2. Gender specific prevalence in Japan 53
3.8.3. Sub-type specific prevalence in Japan 54
4. Appendix 124
4.1. Report Methodology 124
5. Consulting Services 126
6. Disclaimer 127
7. About DelveInsight 127

Table 1: Prevalent Population of Epilepsy in the United States (2016-2027) 22
Table 2: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027) 23
Table 3: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027) 24
Table 4: Prevalence of TSC associated Epilepsy in the United States (2016-2027) 25
Table 5: Prevalent Population of Epilepsy in the Germany (2016-2027) 27
Table 6: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027) 28
Table 7: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027) 29
Table 8: Prevalence of TSC associated Epilepsy in the Germany (2016-2027) 30
Table 9: Prevalent Population of Epilepsy in the France (2016-2027) 32
Table 10: Gender specific Prevalent Population of Epilepsy in the France (2016-2027) 33
Table 11: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027) 34
Table 12: Prevalence of TSC associated Epilepsy in the France (2016-2027) 35
Table 13: Prevalent Population of Epilepsy in the Italy (2016-2027) 37
Table 14: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027) 38
Table 15: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027) 39
Table 16: Prevalence of TSC associated Epilepsy in the Italy (2016-2027) 40
Table 17: Prevalent Population of Epilepsy in the Spain (2016-2027) 42
Table 18: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027) 43
Table 19: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027) 44
Table 20: Prevalence of TSC associated Epilepsy in the Spain (2016-2027) 45
Table 21: Prevalent Population of Epilepsy in the United Kingdom (2016-2027) 47
Table 22: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027) 48
Table 23: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027) 49
Table 24: Prevalence of TSC associated Epilepsy in the UK (2016-2027) 50
Table 25: Prevalent Population of Epilepsy in the Japan (2016-2027) 52
Table 26: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027) 53
Table 27: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027) 54


Figure 1: ILAE 2017 Classification of Seizure Types Basic Version 12
Figure 2: ILAE 2017 Classification of Seizure Types Extended Version 13
Figure 3: Classification of Epilepsy 14
Figure 4: Prevalent Population of Epilepsy in the United States (2016-2027) 22
Figure 5: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027) 23
Figure 6: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027) 24
Figure 7: Prevalence of TSC associated Epilepsy in the United States (2016-2027) 25
Figure 8: Prevalent Population of Epilepsy in the Germany (2016-2027) 27
Figure 9: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027) 28
Figure 10: Sub-type specific Prevalent Population of Epilepsy in the Germany (2016-2027) 29
Figure 11: Prevalence of TSC associated Epilepsy in the Germany (2016-2027) 30
Figure 12: Prevalent Population of Epilepsy in the France (2016-2027) 32
Figure 13: Gender specific Prevalent Population of Epilepsy in the France (2016-2027) 33
Figure 14: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027) 34
Figure 15: Prevalence of TSC associated Epilepsy in the France (2016-2027) 35
Figure 16: Prevalent Population of Epilepsy in the Italy (2016-2027) 37
Figure 17: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027) 38
Figure 18: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027) 39
Figure 19: Prevalence of TSC associated Epilepsy in the Italy (2016-2027) 40
Figure 20: Prevalent Population of Epilepsy in the Spain (2016-2027) 42
Figure 21: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027) 43
Figure 22: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027) 44
Figure 23: Prevalence of TSC associated Epilepsy in the Spain (2016-2027) 45
Figure 24: Prevalent Population of Epilepsy in the United Kingdom (2016-2027) 47
Figure 25: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027) 48
Figure 26: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027) 49
Figure 27: Prevalence of TSC associated Epilepsy in the UK (2016-2027) 50
Figure 28: Prevalent Population of Epilepsy in the Japan (2016-2027) 52
Figure 29: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027) 53
Figure 30: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027) 54


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ てんかん(癲癇)の疫学予測(Epilepsy -Epidemiology Forecast)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆